Axplora, a German CDMO that specializes in API small molecule and ADC production, will upgrade its manufacturing facility in Mourenx, France, with the help of an unnamed customer.
The €50 million project will boost Axplora’s overall peptide purification strength and support the development of new biologic therapies, including GLP-1 drugs to treat diabetes and obesity, the company said in a Feb. 12 press release.
Construction on the expansion is expected to begin immediately and be ready for Biologic License Application status with the FDA by May 2025. The company, which previously operated under the name Novasep, added that it expects to be manufacturing approved GLP-1 therapies in 2026.
After Axplora issued its press release, a spokesperson for the company clarified that the investment "is being made by the customer, rather than Axplora itself."
The company, which traces its origins back to 1995, took on the Axplora moniker after Novasep and PharmaZell merged in 2022.
A year earlier, Novasep pumped €4 million ($4.83 million at the time) to boost capacity to produce highly potent active pharmaceutical ingredients (HPAPIs) at its facility located in Le Mans, France.
Axplora operates ten sites across Europe, India and the U.S., according to its website, employing 2,400 people around the globe.